Cytyc invests in endometriosis
This article was originally published in The Gray Sheet
Women's healthcare firm views a less-invasive, serum-based diagnostic test presently being developed by Valeo Medical for detecting endometriosis as having "excellent potential" to become a successful product. Cytyc announced making an equity investment in Valeo Nov. 9. A Valeo spokesperson says the firm is in preclinical development for the test, having completed feasibility studies on more than 450 human samples demonstrating acceptable levels of specificity and sensitivity. An estimated 7 mil. women suffer from endometriosis in the U.S. each year. Cytyc extended its women's health portfolio with a $325 mil. acquisition of NovaSure menorrhagia treatment manufacturer Novacept on March 1 (1"The Gray Sheet" March 8, 2004, p. 21)...
You may also be interested in...
Cytyc will double its sales force targeting ob/gyn physicians to 200 reps following its acquisition of Novacept, in an effort to make NovaSure the top-selling menorrhagia treatment system
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.